INSECTICIDAL TOXINS FROM THE PARASITIC WASP BRACON HEBETOR

Abstract: Novel polypeptides are isolated from the venom of the parasitic wasp, Bracon hebetor, and are designated Brh-I to Brh-V. These polypeptides are paralytic and/or toxic to insects. The entire amino acid sequence of Brh-I and the DNA encoding it is also determined. These polypeptides may be cloned into a baculovirus, and used for insect control.

Description: ΪNSECTICIDAL TOXINS FROM THE PARASITIC WASP BRACON HEBETOR This invention is directed to toxins active against insects which are isolated from the parasitic wasp Bracon hebetor, the nucleic acids which encode the toxins, cloning of the toxins, use of the toxins to control insects, and genetically engineered virus vectors carrying the toxin gene. BACKGROUND OF THE INVENTION In recent years, venoms of insects and arachnids, in particular spiders and scorpions, have been investigated as a potential source of biologically active substances for use in various fields such as medicine and agriculture. Examples of such work include: EP Patent Application, Publ. No. 208 523 A2: Glutamate Antagonists Isolated from New World Spiders Argiope trifasciata and Araneus gemma. EP Patent Application, Publ No. 156 540: Glutamate Receptor Inhibitor obtained from Nephila clavata. Grishin et al., 1986. "Ion Channel Blocker from the Venom of Argiope lobata" Biorg. Khim. 12(8): 1121-1124. Usherwood et al., 1984. "Glutamate Channel Blockade by Venoms of Argiope trifasciata and Araneus gemma" J. Phvsiol. Paris 79:241-245. Aramaki et al. 1986. "Glutamate Potential Suppressor from Nephila clavata and Nephila maculata" Proc. Japan Acad. 62, Ser B:359-362. Usherwood et al., 1985. "Antagonism of Glutamate Receptor Channel Complexes by Spider Venom Polypeptides" Neurotoxicology 6(2):239-250. Adams et al. 1986. "Synaptic Toxins from Agelenopsis aptera" Insect Neurophvsiology, Borkovec et al., Eds. Humana Press, Clifton, NJ 397-408. Bracon hebetor (also known as Habrobracon hebetor and Microbracon hebetor) is a small (ca. 2 mm, less than 1 mg) ectoparasitic wasp, which has a venom that is paralytic to lepidopte ans (Drenth, D. 1974, Toxicon 12:189-192). The quest to identify toxins in _ 1 hebetor venom has continued for several years (see, e.g. Visser et al, 1976, Toxicon 14:357- 307; Visser et al, 1983, Comp. Biochem. Phvsiol. 75B:523-530; and Spanjer et al, 1977, Toxicon 15:413-421). Most attempts have been frustrated by the lability of the toxins. Two protein toxins (mol. wt. 44 and 57 kda) have been purified and partially characterized, but they represent only 2% of the original insecticidal activity (Visser et al, supra, 1983). More recently, Slavnova et al i-1987 Dokladv Akademii Nauk USSR 297:492-494 reports isolation of a toxin having a mass of 18 kda. DESCRIPTION OF THE INVENTION It has now been found that certain polypeptides, when isolated from the venom of the wasp Bracon hebetor are toxic, i.e. paralytic and/or lethal to insects, particularly of the order Lepidoptera, at surprisingly low concentrations. The present invention, therefore, concerns toxins free from associated wasp polypeptides which demonstrate toxicity towards insects. These polypeptides may be isolated from, or be constructed to show substantial sequence homology to polypeptides isolated from the venom of Bracon hebetor. Preferred peptides are rather large, and may be characterized in having a molecular weight which exceeds 70,000 da. Five preferred polypeptides were isolated and were designated Brh-I to Brh-V. As used throughout the specification and claims, the following definitions are intended: Associated wasp polypeptides— polypeptides naturally occurring in the venom of B. hebetor which are toxic to insects. Homologous polypeptide— a polypeptide which is identical to one of the native toxins of this invention, or substantially homologous (at least 80%) with respect to the amino acid sequence, such that it demonstrates substantially the same insect toxicity in in vivo assays as a native toxin. Homologous nucleotide sequence- a sequence which will hybridize to the reference sequence under stringent hybridization conditions. Stringent hybridization conditions— those in which hybridization is effected in a standard manner at 65°C in 4X buffered saline (a.k.a. SSPE buffer) followed by merely washing at 52°C in 0.2 X SSPE, which will not affect true hybrids which have formed. DESCRD?TION OF THE FIGURES Figure 1 demonstrates the purification of toxins from 300 B. hebetor venom glands using anion-exchange chromatography. Figure 2 is the reversed-phase HPLC analysis of combined fractions 7-13 from Figure 1, using 25 gland-equivalents. Figure 3 is the reversed-phase HPLC analysis of Fraction 8 from Figure 1 (25 gland equivalents). This is predominantly Brh-I. Figure 4 is the reversed-phase HPLC analysis of Fraction 11 from Figure 1 (25 gland equivalents). This is predominantly Brh-V. Figure 5 is the size-exclusion HPLC analysis of toxins from 80 B. hebetor venom glands. Figure 6 is a diagram of plasmid pSCI810, containing the Brh-I gene. Fi ure 7 is a diagram of plasmid pSCI277, containing the Brh-I gene linked to the p 10 promoter. The toxins of this invention are quite labile under many isolation conditions. As they are particularly unstable at low pH, reverse-phase HPLC was contraindicated. The successful structure elucidation of toxins which are part of this invention is predicated on the purification by anion-exchange chromatography which was monitored by reversed-phase HPLC. The results of the anion-exchange chromatography are shown in Figure 1. Various fractions, designated Fractions 7-13 are identified, and their insect mortality is assessed. As ultraviolet absorbance was of limited utility during toxin purification by ion- exchange, short (1 min) fractions were collected relative to contaminant absorbance (280 nm) and each fraction was assayed for bioactivity and purity (typically 25 gland equivalents using reverse-phase HPLC). Results are illustrated in Figures 2, 3, and 4. In order to consistently recover toxins exhibiting high bioactivity, it was necessary to add a protein carrier (bovine serum albumin) prior to desalting by membrane filtration. Purified toxins could not be freeze-dried, even in the presence of BSA and were best stored in a solution (0.02 M ammonium carbonate, pH 9.2, 4°C). Under these conditions, the toxins were stable for at least two weeks. Thus one aspect of this invention is a polypeptide free from associated wasp polypeptides substantially homologous to a polypeptide isolated from Bracon hebetor and exhibiting insect toxicity. Preferred polypeptides have a molecular weight of at least 70,000 da. Examples of prefered polypeptides of this invention include: Brh-I, Brh-II, Brh-III, Brh-IV and Brh-V. The prefeπed polypeptides of this invention may be characterized by their behavior during Anion-Exchange and Reversed-Phase HPLC as follows, the complete conditions of which are given in Example 1. By following the procedures set forth in Example 1, ie. Anion- Exchange chromatography followed by Reversed-Phase chromatography, peaks characteristic of Brh-I, Brh-π, Brh-HI, Brh-IV, and Brh-V can be identified. Three of the five native toxins were sequenced at least partially. Results are presented below. TABLE 1 1 5 10 15 20 25 Brh-I T D F Y Y T D V I AD Q D F L L K Q K K V F Q L .Brh-V H V Q T Y T A D M D F K H K Q K K I Y H L F - - Brh-III L F D F I V H A K D I L G G I D N L A K G I - I/Q 30 35 40 Brh-I L Y H V S Q P - I S N F Q - r- L K (SEQ. ID. NO. : 1) Brh-V Q (SEQ. ID. NO.: 2) - Brh-III A I N K V V I - K V Q - Q A (SEQ. ID. NO. : 3) The polypeptides of this invention may be prepared by a variety of techniques. They may, for example, be isolated from the crude venom of B. hebetor using purification techniques, such as those presented in the Examples. Alternatively, with knowledge of the amino acid sequence of the polypeptides, synthetic construction, using conventional protein synthesis techniques may be employed. A further technique which may advantageously employed in the production of polypeptides of this invention involves the construction, by conventional methods, of a DNA sequence which, upon expression, encodes a polypeptide according to this invention. Such DNA sequences may then be inserted into an appropriate vector, either alone or in combination with other homologous or heterologous DNA sequences whose function may be to control the expression of the polypeptide-encoding DNA sequence of interest or may result in, for example, a fusion protein, enhancing or extending the activity of the toxin DNA expression product therefrom. Suitably employed as vectors are plasmids, phages, and viruses, the use of which for such purpose is common knowledge to the ordinary artisan. Cells in which a vector containing such a toxin DNA may be expressed, include, for example, prokaryotic cells such as E. coli. and Bacillus spp., or eukaryotic cells such as yeast cells or insect cells. A preferred method for producing the toxin polypeptides directly as a toxic product such that no work-up towards isolation, purification, and formulation of an expression product is required is by employing an insect specific virus (baculovirus) as a vector. A gene encoding the desired polypeptide toxin is inserted into the baculovirus DNA, and is under the control of a baculovirus promoter. After the recombinant hybrid baculovirus is ingested by the insect, the virus multiplies inside the insect and the toxin is expressed (produced) in an amount sufficient to enhance the virus' insecticidal effect on the insect. Such a recombinantly modified baculovirus DNA may also be used as a vector for the introduction of the wasp toxin-producing gene into cells, particularly insect cells, to provide further systems for the production of toxins. A number of baculoviruses are suitable for use as vectors, and are known in the art, such as the nuclear polyhedrosis virus from Autographa californica, Heliothis virescens. and Bombvx mori. Suitable techniques are described, for example in European Patent Application 0175 852 and U.S. Patent 4,745,051, both of which are hereby incorporated by reference. Thus, other aspects of this invention are nucleic acids sequences (RNAs and DNAs) comprising those which encode toxin polypeptides and nucleic acid sequences which are substantially homologous to a native sequence. The nucleic acid sequences of this invention may also include sequences which are not expressed in the final polypeptide product, such as signal sequences, termination sequences, and the like. A further aspect of this invention, therefore involves the cloning and genetic engineering of genes encoding the various toxins, and in particular Brh-I. While Brh-I is presented as an Example, any of the polypeptides of this invention may be similarly sequenced and cloned. Starting with approximately 3.1 g of wasps, approximately 8 μg of poly A+ mRNA was obtained using the procedures detailed in the Examples. Degenerate oligonucleotide primers corresponding to two regions of the nucleotide sequence obtained by reverse translation of the mature Brh-I peptide were synthesized and used for PCR amplification from B. hebetor mRNA. DNA fragments with the expected size of approximately 130 bp were produced in the PCR reaction. The DNA fragments were gel purified, cloned into pTZ18R, and three clones were sequenced. All three of these clones contained a reading frame that matched a portion of the amino acid sequence of mature Brh-I toxin. A nondegenerate primer designed to match a region from within the amplified sequence was end-labelled with 32 P and used to screen a λZAPII cDNA library made from B.hebetor. Three positive plaques were detected in a library screening of approximately 1.2 X 10 6 plaques. After plaque purification and in vivo excision of the cDNA containing pBluescript SK- plasmids from the λZAPII clones, the cDNA inserts of 3 clones were, subjected to DNA sequence analysis. In order to determine the expected size of a full length cDNA, a primer extension reaction was performed with B. hebetor mRNA. The nucleic acid and amino acid sequence of Brh-I is given in TABLE 2 (SEQ. ID. NO.: 4 and SEQ. ID. NO.: 5). Translational initiation very likely occurs at the ATG as indicated in TABLE 2 because a) this is the first methionine codon encountered in the cDNA; b) the codon for methionine is found in the sequence ATAATGC, which conforms with the ribosome initiation site consensus sequence determined by Kozak, M., 1989, J. Cell Biol. 108:229-241; and c) there is a translational stop sequence, TAA, in frame with the Brh-I open reading frame just upstream from this methionine codon. The predicted translation product for the cDNA is a molecule of 678 amino acids. The amino acid sequence given in TABLE 2 has an 18 amino acid sequence at the N-terminus preceding the sequence determined by analysis of the isolated polypeptide (Table 1). As this 18 amino acid sequence has many of the properties expected for a signal sequence (see, e.g., von Heijne, G. Nucl. Acids Res. 14:4683-4690) it appears that this sequence is a signal sequence which is cleaved after translation. The molecular weight of mature Brh-I predicted from the cDNA sequence is 77,912. This is somewhat larger than the value determined by SDS-PAGE analysis of isolated Brh-I (approximately 73,000), however, the amino acid composition determined for Brh-I and for the cDNA translation product agree within experimental error, suggesting that no other extensive proteolytic processing occurs besides signal sequence cleavage. Because of the very high level of paralytic activity that Brh-I elicits upon injection of a number of different insects, cDNAs encoding Brh-I toxin may be cloned in an insect baculovirus. Upon expression in the insect, there will be a quicker cessation of feeding than occurs after infection with wild type baculoviruses. Insect baculoviruses occur in two forms, occluded viruses, which are responsible for the spread of viruses between insects, and nonoccluded or budded viruses which are responsible for the cell to cell spread of viruses within an infected insect. Infection of insects per os normally requires the occluded form of the virus. Thus a further aspect of this invention is a recombinant virus containing a gene encoding a toxin of this invention inserted at a locus such that occlusion body formation is not disrupted. One such locus is the plO locus. Polypeptides isolated from or those showing substantial homology to those isolated from the venom of B. hebetor are useful as insect toxic agents. In particular, they are useful toxic agents against insects of the order Lepidoptera, for example, Heliothis virescens, Autographa califomica, and the insects of the genus Spodoptera. Both the purified toxin and viruses transformed to produce the toxin are assayed for bioactivity on larvae including: tobacco hornworms (Manduca sexta), tobacco budworms (Heliothis virescens) and beet armyworm (Spodoptera exigua). Toxicity is demonstrated by the ability of the polypeptides to cause paralysis and/or death of the test larvae. The present invention also provides the use of polypeptides isolated from, or polypeptides showing substantial sequence homology to those isolated from Bracon hebetor as insect toxic agents. For use as insecticides, the recombinant viruses which produce polypeptides of the invention may be combined with suitable carrier substances such as those typically found in insect control formulations, .such as adjuvants, diluents, modifiers or conditioning agents. The formulations may be in the form of solutions, emulsions, dispersions, powders, dusts, granules and the like. It may be advantageous to include a surface active agent such as DMSO in the formulation so that the toxin passes directly through the cuticle of the insect and avoids the digestive enzymes which might affect its activity. These compositions are advantageously applied to the insect or its locale in an amount suitable to control the target insects. By control, as used herein, is meant the induction of paralysis, mortality, or cessation of eating. Dosages of the composition of the invention will depend on numerous factors, including the pest to be controlled and the climatic conditions, but will generally be in the range of 0.5 to 100 kg/hectare, preferably 10-50 kg/hectare. The following non-limiting Examples are presented to better illustrate the invention. EXAMPLE 1 Isolation of Toxins B. hebetor adult wasps are purchased from Biofac, Inc., Mathis TX. Upon arrival, wasps are frozen at -20°C until used. Venom glands and associated tissue are removed from female wasps and are stored in 1.5 ml polypropylene tubes at -20°C until processed. Purification. Lots of 100 venom glands are homogenized manually with a glass pestle in 1 ml water. After centrifugation at 3000 x g, the supematants from 300 glands are passed through Bio-Rad 10 DG size-exclusion columns. The excluded fraction (mol. wt >6 kda) is purified by ion-exchange chromatography. Anion-exchange chromatography is performed with a Perkin-Elmer pump (410 BIO), a Spectra-Physics ultraviolet detector (Model 8300, 280 nm) and an Altex column (Spherogel- 8 TSK, DEAE-5PW, 7.5 X 75 mm) with a elution at 1 ml/min. The elution solvent is citrate in 0.02 M ammonium carbonate containing 10% aceto-nitrile, pH 8.2: 0 mM citrate for 15 min, linear gradient to 25 mM over 5 min, and 25 to 75 mM over 50 min. Individual fractions are bioassayed using M. sexta larvae. As shown in Figure 1, all insecticidal activity is found in one broad zone (Fractions 7-13). Collectively, these fractions contain several wasp toxins (See Fig. 2, 3 and 4), but only 59 μg total protein from 300 venom glands, representing an approximately 4000-fold purification of toxins based on initial whole wasp mass. Reverse phase liquid chromatography (HPLC) is performed using a Hewett Packard (HP) pump (Model 1090), an HP diode array detector (Model 1040, 220 and 280 nm), and a narrow-bore Vydac C 4 -300 A column (15 X 0.2 cm) with a flow rate of 0.3 ml/min. The eluent is acetonitrile in 0.1% trifluoroacetic acid: 35% for 5 min, linear gradient 35 to 60% over 25 min. HPLC demonstrates that most individual fractions from ion-exchange chromatography are mixtures of toxins. However, fractions 8 and 11 are sufficiently pure to allow further characterizations. Fraction 8 contains predominandy Brh-I while Fraction 11 contains mostly Brh-V (See Figs. 3 and 4). Size-exclusion chromatography employed the same Perkin-Elmer pump and Spectra- Physics detector as above with an Altex Spherogel-TSK 3000SW column (7.5 x 300 mm) with a flow of 0.5 ml/min. The eluent is 10% acetonitrile. Results are shown in Figure 5. EXAMPLE 2 BIOASSAY The bioactivity of whole venom glands is determined for 50 glands homogenized in ice water. After centrifugation at 3000 x g, 3 μl aliquots are injected into the pronotum of lepidopteran larvae which are scored for mortality at 24 hrs. The lethal dose for 50% of the treated larvae (LD 50 ) is calculated by Probit analysis from duplicate lots of glands, each of with at least four dose rates. Purified Brh-I and Brh-V toxins are assayed similarly. Prior to the bioassay, 1 min. fraction from the ion-exchange purification are desalted using Centricon®-10 microconcentrators (Amicon). Bovine serum albumin (100 μg) is added to samples prior to desalting to improve recovery of toxins. Toxins are concentrated to approximately 150 μl in 0.02 M ammonium carbonate for bioassay. The following larvae are bioassayed: Manduca sexta (tobacco hornworm) third stadium; Heliothis virescens (tobacco budworm) fourth stadium; Helicoverpa zea (corn earworm) fourth stadium; Spodoptera exigua (beet armyworm) fifth stadium; Galleria mellonella (wax moth) fourth stadium; Trichoplusia ni (cabbage looper) fifth stadium; Pieris rapae (cabbage butterfly) third stadium; and Diabrotica undecimpunctata (western spotted cucumber beede) third stadium. Results are presented in Tables 3 and 4, below. TABLE 3 -- Bioactivity of Venom Gland Extract 0.036 0 .77 0.080 1.7 0.065 1.3 0.00046 0 . 0076 0.038 0 . 95 0.0014 0 . 021 >0.2 >13 0.000073 0 . 0013 TABLE 4 Injection Assay Duplicate toxin isolation for bioassay 10 EXAMPLE 3 Sequence Analysis 900 venom glands are processed as described above. Purified toxins (43-77 pmol) are sequenced twice using an Applied Biosystems Model 477A pulsed liquid phase protein sequencer. Released phenylthiohydantoin amino acids are analyzed using an on-line analyzer (Applied Biosystems Model 120A). Brh-I is also converted to a reduced, carboxymethylated derivative prior to sequencing as described in Skinner et al, 1989 J. Biol. Chem. 264:2150- 2155, which is hereby incorporated by reference. Toxins Brh-I and Brh-V are analyzed for constituent amino acids after hydrolysis in vacuo by vapor from 6 M HC1/1% phenol at 110°C for 20 hrs. Hydrolysates are analyzed using a Hewlett Packard AminoQuant amino acid analyzer. EXAMPLE 4 - Isolation of mRNA B. hebetor wasps are stored at -80°C. 3.15 g of both male and female wasps are homogenized with a Polytron for 1 min in 20 ml RNA extraction buffer (4 M guanidine isothiocyanate, 50 mM sodium citrate, pH 7.0, and 0.1 M 2-mercaptoethanol). Following homogenization, 1 ml 15% Sarkosyl is added. The homogenate is centrifuged at 8,000 rpm for 10 min at 4°C in a Sorvall HB-4 rotor, and the supematants are decanted into clean tubes to remove insoluble debris. This is repeated once and the supernatant is layered over 3 ml of 5.7 M CsCl in 0.01M EDTA, pH 8.0, and is centrifuged for 17 hours at 35,000 rpm in a Beckman Ti55 rotor. The pellet is resuspended in 15 ml of FastTrack Lysis Buffer (Invitrogen Corp) and the mRNA is then isolated following the protocol provided by Invitrogen Corp for their FastTrack mRNA isolation kit. 11 EXAMPLE 5 PCR Amplification Single-stranded cDNA is synthesized from.B. hebetor mRNA (0.5 μg) using M-MLV reverse transcriptase (GIBCO-Bethesda Research Laboratories) primed with a degenerate 20- mer oligonucleotide primer with the following sequence (SEQ. ID. NO.: 6) 5'-A[A,G] [C,T]TG [A,G] AA[ACGT] AC[C,T]TT[C,T]TT[C,TlTG-3 ' This primer is complementary to a sequence derived by reverse translation of the Brh-I toxin N-terminal amino acid sequence. Following the cDNA synthesis, the reactions are heated to 90°C for 5 minutes, cooled to room temperature and ethanol precipitated. The cDNA reaction product is amplified in a 50 μl reaction with PCR geneAMP reagents (Perkin-Elmer Cetus Instruments), using 2 μM each of the above primer and a second degenerative primer with the following sequence (SEQ. ID. NO.: 7): 5'-GA [C,T]TT[C,T]TA[C,T]TA[C,T]AC[A,C,G,T]GA[C,T]GT-3' This primer corresponds to a second portion of the reverse translation product of the Brh-I toxin N-terminal amino acid sequence. PCR conditions are as follows: 1 min at 94"C; 2 min at 37°C; slow ramping of the temperature over 3 min to 72°C; 3 min at 72°C; 10 sec extension of the 72 β C segment per cycle for 30 cycles; and a final cycle extension of 72°C segment for 10 min. The products of the PCR reaction are electrophoresed on a 2% Agarose gel in TBE buffer (Sambrook et al, 1989 Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). A gel slice expected to contain the approximately 70 bp product is removed, and die DNA is isolated using Geneclean (BiolOl) reagents according to the manufacturer's instructions. The DNA is then reamplified using the same primers and the same PCR conditions as described above. The DNA fragments are then gel-purified and cloned into pTZ18R (BIO-RAD Laboratories) and three clones are sequenced. All three clones match the Brh-I sequence from Table 1. A non-degenerate primer, designed to match a region from within the amplified sequence (See Table 5) is end-labeled with 32 P and used to screen a λZAPII cDNA library made from B. hebetor mRNA. Three positive plaques are detected in a library screening of 12 approximately 1.2 X 10° plaques. One of the Brh-I positive clones has an insert size of approximately 3.0 kb, and the other two each have inserts of approximately 2.3 kb. TABLE 5 Reverse translation and PCR Amplification of Brh-I toxin mRNA. The amino acid sequence of amino acids 2 through 32 from the N-terminus of Brh-I toxin is shown on line 1. The nucleotide sequence derived by reverse translation of the Brh-I amino acid sequence is shown below the amino acid sequence on line 2. All possible nucleotides at each position are indicated; Y= C or T; R= A or G; M= A or C; W= A or T; H= A, C, or T; N= A, C, T, or G. Degenerate oligonucleotides corresponding to the first underlined region and the complement of the second underlined region are used as PCR primers for amplification from Brh-I mRNA. Lines 3, 4, and 5 show the nucleotide sequence from three cloned PCR fragments. Underlined sequences correspond to primer regions. Line 6 shows the sequence of the nondegenerate oligonucleotide which was used as a hybridization probe for screening the B. hebetor cDNA library. 5 10 15 1 Thr Asp Phe Tyr Tyr Thr Asp Val lie Ala Asp Gin Asp Phe Leu Leu Lys Gin 2 ACN GAY TTY TAY TAY ACN GAY GTN ATH GCN GAY CAR GAY TTY YTN YTN AAR.CAR 3 GAT TTT TAT TAT ACT GAT GTG ATA GCT GAT CAA GAT TTC CTT TTA AAG CAA 4 GAC TTT TAT TAC ACT GAC GTG ATA GCT GAT CAA GAT TTC CTT TTA AAG CAA 5 GAT TTT TAT TAT ACT GAT GTG ATA GCT GAT CAA GAT TTC CTT TTA AAG CAA 6 3'-CAC TAT CGA CTA GTT CTA AAG G-5' (SEQ. ID. NO. : 8) 20 25 30 1 Lys Lys Val Phe Gin Leu Leu Tyr His Val Ser Gin Pro 2 AAR AAR GTN TTY CAR YTN YTN TAY CAY GTN SN CAR CCN 3 4 5 DNA sequencing and Sequence Analysis. Double stranded pBluescript SK- plasmid DNA containing cDNA inserts are generated from λZAPII cDNA clones following the in vivo excision procedure described in the λZAPII instruction manual. The 5 '-termini of the cDNA inserts are then subjected to PCR amplification using the primer indicated in Table 5 coupled with Ml 3 reverse primer. The PCR products from the 5 '-termini of the 2.3 kb cDNA inserts 13 have identical sequences and that from the 3.0 kb cDNA sequence is the same as those of the 2.3 kb cDNA except for being shorter by four nucleotides. The two Xhol fragments from within the cDNA insert are subcloned into the pBluescriptSK+π vector, and unidirectional deletion series are generated from both ends of each clone. Both strands of the cDNA are sequenced in their entirety, and is given in Table 2 (SEQ. ID. NO. 4 and SEQ. ID. NO.: 5). The nucleotide sequences and predicted protein sequences are analyzed with the IntelliGenetics suite of sequence analysis programs. EXAMPLE 5 Construction of Vectors A plasmid containing the Brh-I cDNA is liberated from a recombinant λZAPII isolate by in vivo excision. The plasmid is cut with Xbal and Kpnl, treated with Klenow in the presence of all four dNPTs to make the ends blunt, and then the cDNA containing insert is gel isolated. The plasmid pACJJ2, (obtained from Dr. Just Vlak, Dept. of Virology, Agricultural Univ., Wageningen, The Netherlands) which has a polylinker in place of the complete lO open reading frame, is cut with Ba HI, the ends are filled, phosphatased with calf intestinal phosphatase, and then is ligated with the isolated Brh-I cDNA to form pSCI810, as shown in Figure 6. Next, pBluescript KS + and pBluescript SK + are each digested witii Kpnl and Xholl, treated with Klenow in the presence of dNPT's to make the ends flush, and then religated to form pBluescript KS + ΔXK and pBluescript SK + ΔXK, respectively. Each of these plasmids is then digested with Seal and Sail. The larger of the two fragments from the Seal and Sail digested pBluescript KS + ΔXK and the smaller of the two fragments from the Seal and Sail digested pBluescript SK + ΔXK are isolated and ligated together to form pSCI235. Another plasmid, pSCI839 is constructed by . subcloning an approximately 3 kb Sail fragment containing an intact polyhedrin gene into pSCI234 to form pSCI839. The Sail fragment 14 containing th„ polyhedrin gene in pSCI839 is isolated from pSCI275, which is a pWE15-based cosmid vector containing a large segment of AcNPV DNA (randomly cloned from AcNPV strain LI) that includes the polyhedrin gene. Plasmid pSCI276 is formed by cutting pSCI810 with PstI and Spel, making the ends blunt with T 4 DNA polymerase in the presence of dNTPs, and is religated. pSCI276 is then cut with SphI and Smal, the SphI ends are made flush with T 4 DNA polymerase in the presence of dNTPs, and ah approximately 2650 bp segment containing the Brh-I cDNA linked to the plO promoter is isolated and cloned into the unique EcoRV site of pSCI839 to form pSCI277. The plasmid pSCI277 has a module containing the plO promoter region linked to the Brh-I cDNA inserted at the EcoRV site just upstream of the intact polyhedrin gene; it is diagrammed in Figure 7. After transfection of this plasmid with polyhedrin ' viral plasmid DNA, recombinant viruses are selected by their ability to form polyhedra* plaques. 15 TABLE 2 BRH-I (SEQ/ ID. NOS. 4 & 5) GCAACACAAG TGTTACTTCG TTTGCCACTT CACTGTTGAA GAAAAATAAA AAATACATTT 60 TGATTATCAC TTGAATAATC TATA ATG CTG AAG AAG GTC TTT CTT TTG GCC 111 Met Leu Lys Lys Val Phe Leu Leu Ala 1 5 TCT TTG GCT ATT ATC GTG ATA AAA GCT GAT ACC GAT TTT TAT TAT ACA 159 Ser Leu Ala lie lie Val lie Lys Ala Asp Thr Asp Phe Tyr Tyr Thr 10 15 20 25 GAT GTG ATA GCT GAT CAA GAT TTC CTT TTA AAG CAA AAG AAA GTT TTT 207 Asp Val lie Ala Asp Gin Asp Phe Leu Leu Lys Gin Lys Lys Val Phe 30 . 35 40 * CAA TTG TTG TAT CAT GTT TCA CAA CCA GAC ATC TCA AAT CCC GAG CTT 255 Gin Leu Leu Tyr His Val Ser Gin Pro Asp lie Ser Asn Pro Glu Leu 45 50 55 TTC CAG GAG GGA TTG GCT TAT GAC ATT GGA GCC AAT ATT GAT TCC TAT 303 Phe Gin Glu Gly Leu Ala Tyr Asp lie Gly Ala Asn lie Asp Ser Tyr 60 65 70 TCT AAT AAG GAT GCA GTG AAT C C TTC CTC GAG CTA TAC AAA TTC GGA 351 Ser Asn Lys Asp Ala Val Asn His Phe Leu Glu Leu Tyr Lys Phe Gly 75 -80 85 TTC CTT CCA AGA GGT GCA ATC TAC TGG GTC TAT TAT CCT AAA CTC TTG 399 Phe Leu Pro Arg Gly Ala lie Tyr Trp Val Tyr Tyr Pro Lys Leu Leu 90 95 100 - 105 GAC GAG ACT AAA GCC TTG TTC AAA TTG TTC TAC TAT GCC AAG GAC TTT 447 Asp Glu Thr Lys Ala Leu Phe Lys Leu Phe Tyr Tyr Ala Lys Asp Phe 110 115 120 GAT ACT TTC TAT AAA ACT GCC CTT TGG GCG AGA AAT CGT TTG AAC GAA 495 Asp Thr Phe Tyr Lys Thr Ala Leu Trp Ala Arg Asn Arg Leu Asn Glu 125 130 135 GGT GAA TTC ATA TGT GCC TTC TAT GAA GCT GTC ATC CGG CGT CCC GAC 543 Gly Glu Phe lie Cys Ala Phe Tyr Glu Ala Val lie Arg Arg Pro Asp 140 145 150 ACA GAG TAT CTC CAG TTA CCA CCG CCT TAT GAG TTA TAT CCC TAT GCG 591 Thr Glu Tyr Leu Gin Leu Pro Pro Pro Tyr Glu Leu Tyr Pro Tyr Ala 155 160 165 TTC TTC AAC AGT GAG GTA ATC GAG GCT GCA AAA AAT GCC AAA TTG TAC ' 639 Phe Phe Asn Ser Glu Val lie Glu Ala Ala Lys Asn Ala Lys Leu Tyr 170 175 180 . 185 AAT AAG CTT GTT GAA GGA AAT TCC TAC ATT ATC TAT GTC AAT TAC TCC 687 Asn Lvs Leu Val Glu Gly Asn Ser Tyr lie lie Tyr Val Asn Tyr Ser 190 195 200 GGC TGG TAC TTG AAT CGA GCT TAT GAT ACA GAG ATG AGA GTC AAC TAT 735 Gly Trp Tyr Leu Asn Arg Ala Tyr Asp Thr Glu Met Arg Val Asn Tyr 205 210 215 TTC CTC GAA GAT ATC GGT TTA AAC ACC TTC TAC TTT TTC TAC CGC ATG 783 Phe Leu Glu Asp lie Gly Leu Asn Thr Phe Tyr Phe Phe Tyr Arg Met * 220 225 230 16 TABLE 2, CTD. GAT AAT CCA TTT TGG TTG AGC AGT GAG GAA TTT GGT TTG CAG AAA AAT 831 Asp Asn Pro Phe Trp Leu Ser Ser Glu Glu Phe Gly Leu Gin Lys Asn 235 240 245 TTG CGT GGT GAG GAA TTT CTC TAT GTT CAC AAA ACA CTC TTG AAT CGT 879 Leu Arg Gly Glu Glu Phe Leu Tyr Val His Lys Thr Leu Leu Asn Arg 250 255 - 260 265 TAC AAT TTG GAA AGA TTG GCA AAT GGC TTG GAG AAA ATT GAA GAA TTC 927 Tyr Asn Leu Glu Arg Leu Ala Asn Gly Leu Glu Lys lie Glu Glu Phe 270 275 280 CTT TGG GAG GGA GAA TTT TAT CCA GGC TAT TAT CCA ACT ATG GTC TAT 975 Leu Trp Glu Gly Glu Phe Tyr Pro Gly Tyr Tyr Pro Thr Met Val Tyr 285 290 295 GGC AAT GGG CTG GCT TAT CCT CAG CGT CCA GGA ATG AGT AGG ATT CCT 1023 Gly Asn Gly Leu Ala Tyr Pro Gin Arg Pro Gly Met Ser Arg lie Pro 300 305 310 CCA TAT AAG TAT CAT TAT TTA CGG TAT ATC CAC GAT ATC GAA GAT AGA 1071 Pro Tyr Lys Tyr His Tyr Leu Arg Tyr lie His Asp lie Glu Asp Arg 315 320 325 ATT TCA ACA GCC ATT GAC TTG GGC TAT ATA ATC GAC AGC GAT GGT AGT 1119 lie Ser Thr Ala lie Asp Leu Gly Tyr lie lie Asp Ser Asp Gly Ser 330 335- 340 345 CAC CAC AAC ATC TCA AGT CCC GAA GGA CTT AAC CTC TTA GGT AAC ATC 1167 His His Asn lie Ser Ser Pro Glu Gly Leu Asn Leu Leu Gly Asn lie 350 355 360 ATC GAG GGT AAT GAA GAT AGT TGC AAT AAA AAC TTT TAT CAC AGC CTC 1215 lie Glu Gly Asn Glu Asp Ser Cys Asn Lys Asn Phe Tyr His Ser Leu 365 370 375 GAT TGG TAT GGT AGA AAG GTT CTT GGT TTC AAT CTC GAG CCC AAG ACT 1263 Asp Trp Tyr Gly Arg Lys Val Leu Gly Phe Asn Leu Glu Pro Lys Thr 380 385 390 CCC TAT CAA GTT ATT CCA AGT GCA CTA GAG TCA TTT TCA ACT TGC ATG 1311 Pro Tyr Gin Val lie Pro Ser Ala Leu Glu Ser Phe Ser Thr Cys Met 395 400 405 AGA GAT CCG GCT TTC TAT CGT CTC TAC AAT AGA TAT CTG TCA TAC TGG 1359 Arg Asp Pro Ala Phe Tyr Arg Leu Tyr Asn Arg Tyr Leu Ser Tyr Trp 410 415 420 425 TAC AGA TTC AAA GAA ACC TTG AAG CCA TAT TCT AAG AAT GAA ATA GTC '1407 Tyr Arg Phe Lys Glu Thr Leu Lys Pro Tyr Ser Lys Asn Glu lie Val 430 435 4.40 TTC TCT GAT TTG AAA TTT GAA TCA ATT GCT GTT GAT AAA TTG ATC ACA 1455 Phe Ser Asp Leu- Lys Phe Glu Ser lie Ala Val Asp Lys Leu lie Thr 445 450 455 TAT TTT GAT TAT TTT GAT TCA ACA ATT AGC AAT GGT CTA CCA ATT ACA 1503 Tyr Phe Asp Tyr Phe Asp Ser Thr lie Ser Asn Gly Leu Pro lie Thr 460 465 470 AGT AAA CAA GAT GCT GAT AAT TTA ATG ATC AAA GTT CGC CAG AGT CGT 1551 Ser Lys Gin Asp Ala Asp Asn Leu Met lie Lys Val Arg Gin Ser Arg 475 480 485 17 TABLE 2 CTD. TTA AAT AAT AAA CAC TTT ACC GTA CAT TTC GCC CTA AAT TCC GAT AAA 1599 Leu Asn Asn Lys His Phe Thr Val His Phe Ala Leu Asn Ser Asp Lys 490 495 500 505 GCA CAA AAA GTT GCC ATT CAG CTG TTT CTT GGA CCC AAA TAT GAT GCA 1647 Ala Gin Lys Val Ala lie Gin Leu Phe Leu Gly Pro Lys Tyr Asp Ala 510 515 520 CTT GGT AAT TTA TTG GAC TTT TCC GAG AGT TAC AAA GAC TTT TAT GAG 1695 Leu Gly Asn Leu Leu Asp Phe Ser Glu Ser Tyr Lys Asp Phe Tyr Glu ■ 525 530 535 ATT GAC TAC TGG ATT ACT GAT GTG AAT GCT GGC TTG AAT AAA CTT GAA 1743 lie Asp Tyr Trp lie Thr Asp Val Asn Ala Gly Leu Asn Lys Leu Glu 540 545 550 CGT ACC AGT CAC GAC TTT ATC TTT TTG ATG GCC GAC CGA GAT CCA AGT 1791 Arg Thr Ser His Asp Phe lie Phe Leu Met Ala Asp Arg Asp Pro Ser 555 560 565 GAA ATT TTA TAC AAA AGA GTT TTA AAG GCC CTT GAT GGA AGT GAA AAG 1839 Glu lie Leu Tyr Lys Arg Val Leu Lys Ala Leu Asp Gly Ser Glu Lys 570 575 580 585 TTC ATG TAC AAA AAG AAT TTG TAT GGC ATT CCG GAA CGT TTA CTT CTA 1887 Phe Met Tyr Lys Lys Asn Leu Tyr Gly lie Pro Glu Arg Leu Leu Leu 590 595 600 CCA AAA GGT AAA CGT GCC GGT AGT ATT TTC CAA CTG TTT GCC TAT GTA 1935 Pro Lys Gly Lys Arg Ala Gly Ser lie Phe Gin Leu Phe Ala Tyr Val 605 610 615 AGC CCA GTT ACC CAG CCA GTC ACC TAC AAA TCA CGA GTA TTT GGA TCT 1983 Ser Pro Val Thr Gin Pro Val Thr Tyr Lys Ser Arg Val Phe Gly Ser 620 625 630 TAT CAA TAC TAC ATG AAA CCA GGT GGT TTT CCA CTG GAC AGG CCA ATC 2031 Tyr Gin Tyr Tyr Met Lys Pro Gly Gly Phe Pro Leu Asp Arg Pro lie 635 640 645 TAC TAT CCC CAT TTC CAA GGG CCC AAT ATG TTC TTC AAA GAT ATT ACG 2079 Tyr Tyr Pro His Phe Gin Gly Pro Asn Met Phe Phe Lys Asp lie Thr 650 655 660 ' . 665 ATT TAC CAC AAG ACT GAT GTG GAT CCT AAT GCT ACT ACC TAATTCCAAT 2128 lie Tyr His Lys Thr Asp Val Asp Pro Asn Ala Thr Thr 670 675 TTTTTTACTC TATTTTCATT TGAGATTCTT ATCAAATTCA ATGTTTGTTT GTTAATATTG ' 2188 TCTTTGTAGA GCTTAGAATG TTAGATTGAA AATGTTTATT TCCATGACAA TTTATTATTT 2248 GTTATTGATA TTATCAATGA ATTCTCTGTC AGTCAACCTC AGAGAATATA AAATTTTATT 2308 ACAAAAATGT CGTATTGAGC ATAAATTCAT TATTTGGGAA AAATTTTCAA ATAAAAAGCA 2368 TATTTTCCAA CAAAAAAAA 2387 18 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT:Quistad, Gary B. Leisy, Douglas J. (ii) TITLE OF INVENTION: Insecticidal Toxins fro the Parasitic Wasp Bracon Hebetor (iii) NUMBER OF SEQUENCES: 13 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Sandoz Agro Inc, Patent Dept. (B) STREET: 975 California Ave. (C) CITY: Palo Alto (D) STATE: CA (E) COUNTRY: USA (F) ZIP: 94304-1104 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: • (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Giesser, Joanne M. (B) REGISTRATION NUMBER: 32,838 (C) REFERENCE/DOCKET NUMBER: Z-703 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (415) 354-3588 (B) TELEFAX: (415) 857-1125 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 19 (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Xaa Thr Asp Phe Tyr Tyr Thr Asp Val lie Ala Asp Gin Asp Phe Leu 1 5 10 15 Leu Lys Gin Lys Lys Val Phe Gin Leu Leu Tyr His Val Ser Gin Pro 20 25 30 Xaa lie Ser Asn Xaa Xaa Xaa Phe Gin Xaa Xaa Leu Lys 35 40 45 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Xaa His Val Gin Thr Tyr Thr Ala Asp Met Asp Phe Lys His Lys Gin - 1 5 10 15 Lys Lys lie Tyr His Leu Phe Xaa Xaa Xaa Xaa Gin 20 25 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 20 TE SHEET (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 25..26 (D) OTHER INFORMATION: /label **** AA25 /note= "Amino acid #25 may be I or Q." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Xaa Leu Phe Asp Phe lie Val His Ala Lys Asp lie Leu Gly Gly lie 1 5 10 15 Asp Asn Leu Ala Lys Gly lie Xaa Xaa Ala lie Asn Lys Val Xaa Xaa 20 25 30 Val lie Xaa Lys Val Gin Xaa Gin Ala 35 40 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2387 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 85..2121 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GCAACACAAG TGTTACTTCG TTTGCCACTT CACTGTTGAA GAAAAATAAA AAATACATTT 60 21 TGATTATCAC TTGAATAATC TATA ATG CTG AAG AAG GTC TTT CTT TTG GCC 111 Met Leu Lys Lys Val Phe Leu Leu Ala 1 5 TCT TTG GCT ATT ATC GTG ATA AAA GCT GAT ACC GAT TTT TAT TAT ACA 159 Ser Leu Ala lie lie Val lie Lys Ala Asp Thr Asp Phe Tyr Tyr Thr 10 15 20 25 GAT GTG ATA GCT GAT CAA GAT TTC CTT TTA AAG CAA AAG AAA GTT TTT 207 Asp Val lie Ala ASP Gin Asp Phe Leu Leu Lys Gin Lys Lys Val Phe 30 35 40 CAA TTG TTG TAT CAT GTT TCA CAA CCA GAC ATC TCA AAT CCC GAG CTT 255 Gin Leu Leu Tyr His Val Ser Gin Pro Asp lie Ser Asn Pro Glu Leu 45 50 55 TTC CAG GAG GGA TTG GCT TAT GAC ATT GGA GCC AAT ATT GAT TCC TAT 303 Phe Gin Glu Gly Leu Ala Tyr Asp lie Gly Ala Asn lie Asp Ser Tyr 60 65 * 70 TCT AAT AAG GAT GCA GTG AAT CAC TTC CTC GAG CTA TAC AAA TTC GGA 351 Ser Asn Lys Asp Ala Val Asn His Phe Leu Glu Leu Tyr Lvs Phe Gly 75 80 85 TTC CTT CCA AGA GGT GCA ATC TAC TGG GTC TAT TAT CCT AAA CTC TTG 399 Phe Leu Pro Arg Gly Ala lie Tyr Trp Val Tyr Tyr Pro Lys Leu Leu 90 95 100 105 GAC GAG ACT AAA GCC TTG TTC AAA TTG TTC TAC TAT GCC AAG GAC TTT 447 Asp Glu Thr Lys Ala Leu Phe Lys Leu Phe Tyr Tyr Ala Lys Asp Phe 110 115 120 GAT ACT TTC TAT AAA ACT GCC CTT TGG GCG AGA AAT CGT TTG AAC GAA 495 Asp Thr Phe Tyr Lys Thr Ala Leu Trp Ala Arg Asn Arg Leu Asn Glu 125 130 135 GGT GAA TTC ATA TGT GCC TTC TAT GAA GCT GTC ATC CGG CGT CCC GAC 543 Gly-Glu Phe lie Cys Ala Phe Tyr Glu Ala Val lie Arg Arg Pro Asp 140 145 150 ACA GAG TAT CTC CAG TTA CCA CCG CCT TAT GAG TTA TAT CCC TAT GCG 591 Thr Glu Tyr Leu Gin Leu Pro Pro Pro Tyr Glu Leu Tyr Pro Tyr Ala 155 160 165 TTC TTC AAC AGT GAG GTA ATC GAG GCT GCA AAA AAT GCC AAA TTG TAC 639 Phe Phe Asn Ser Glu Val lie Glu Ala Ala Lys Asn Ala Lys Leu Tyr 170 175 180 185 AAT AAG CTT GTT GAA GGA AAT TCC TAC ATT ATC TAT GTC AAT TAC TCC .687 Asn Lys Leu Val Glu Gly Asn Ser Tyr lie lie Tyr Val Asn Tyr Ser 190 195 200 GGC TGG TAC TTG AAT CGA GCT TAT GAT ACA GAG ATG AGA GTC AAC TAT 735 Gly Trp Tyr Leu Asn Arg Ala Tyr Asp Thr Glu Met Arg Val Asn Tyr 205 ' 210 215 TTC CTC GAA GAT ATC GGT TTA AAC ACC TTC TAC TTT TTC TAC CGC ATG 783 Phe Leu Glu Asp lie Gly Leu Asn Thr Phe Tyr Phe Phe Tyr Arg Met 220 225 230 GAT AAT CCA TTT TGG TTG AGC AGT GAG GAA TTT GGT TTG CAG AAA AAT 831 Asp Asn Pro Phe Trp Leu Ser Ser Glu Glu Phe Gly Leu Gin Lys Asn 235 240 245 22 TTG CGT GGT GAG GAA TTT CTC TAT GTT CAC AAA ACA CTC TTG AAT CGT 879 Leu Arg Gly Glu Glu Phe Leu Tyr Val His Lys Thr Leu Leu Asn Arg 250 255 260 265 TAC AAT TTG GAA AGA TTG GCA AAT GGC TTG GAG AAA ATT GAA GAA TTC 927 Tyr Asn Leu Glu Arg Leu Ala Asn Gly Leu Glu Lys lie Glu Glu Phe 270 275 280 CTT TGG GAG GGA GAA TTT TAT CCA GGC TAT TAT CCA ACT ATG GTC TAT 975 Leu Trp Glu Gly Glu Phe Tyr Pro Gly Tyr Tyr Pro Thr Met Val Tyr 285 290 295 GGC AAT GGG CTG GCT TAT CCT CAG CGT CCA GGA ATG AGT AGG ATT CCT 1023 Gly Asn Gly Leu Ala Tyr Pro Gin Arg Pro Gly Met Ser Arg lie Pro 300 305 310 CCA TAT AAG TAT CAT TAT TTA CGG TAT ATC CAC GAT ATC GAA GAT AGA 1071 Pro Tyr Lys Tyr His Tyr Leu Arg Tyr lie His Asp lie Glu Asp Arg 315 320 325 ATT TCA ACA GCC ATT GAC TTG GGC TAT ATA ATC GAC AGC GAT GGT AGT 1119 lie Ser Thr Ala lie Asp Leu Gly Tyr He He Asp Ser Asp Gly Ser 330 335 340 345 CAC CAC AAC ATC TCA AGT CCC GAA GGA CTT AAC CTC TTA GGT AAC ATC 1167 His His Asn He Ser Ser Pro Glu Gly Leu Asn Leu Leu Gly Asn He 350 355 360 ATC GAG GGT AAT GAA GAT AGT TGC AAT AAA AAC TTT TAT CAC AGC CTC 1215 He Glu Gly Asn Glu Asp Ser Cys Asn Lys Asn Phe Tyr His Ser Leu 365 370 375 GAT TGG TAT GGT AGA AAG GTT CTT GGT TTC AAT CTC GAG CCC AAG ACT 1263 Asp Trp Tyr Gly Arg Lys Val Leu Gly Phe Asn Leu Glu Pro Lys Thr 380 385 390 CCC TAT CAA GTT .ATT CCA AGT GCA CTA GAG TCA TTT TCA ACT TGC ATG 1311 Pro Tyr Gin Val He Pro Ser Ala Leu Glu Ser Phe Ser Thr Cys Met 395 400 405 AGA GAT CCG GCT TTC TAT CGT CTC TAC AAT AGA TAT CTG TCA TAC TGG 1359 Arg Asp Pro Ala Phe Tyr Arg Leu Tyr Asn Arg Tyr Leu Ser Tyr Trp 410 415 420 425 TAC AGA TTC AAA GAA ACC TTG AAG CCA TAT TCT AAG AAT GAA ATA GTC 1407 Tyr Arg Phe Lys Glu Thr Leu Lys Pro Tyr Ser Lys Asn Glu He Val 430 435 440 TTC TCT GAT TTG AAA TTT GAA TCA ATT GCT GTT GAT AAA TTG ATC ACA 1455 Phe Ser Asp Leu Lys Phe Glu Ser He Ala Val Asp Lys Leu He Thr 445 450 455 TAT TTT GAT TAT TTT GAT TCA ACA ATT AGC AAT GGT CTA CCA ATT ACA 1503 Tyr Phe Asp Tyr Phe Asp. Ser Thr He Ser Asn Gly Leu Pro He Thr 460 465 470 AGT AAA CAA GAT GCT GAT AAT TTA ATG ATC AAA GTT CGC CAG AGT CGT 1551 Ser Lys Gin Asp Ala Asp Asn Leu Met He Lys Val Arg Gin Ser Arg 475 480 485 TTA AAT AAT AAA CAC TTT ACC GTA CAT TTC GCC CTA AAT TCC GAT AAA 1599 Leu Asn Asn Lys His Phe Thr Val His Phe Ala Leu Asn Ser Asp Lys 490 495 500 505 23 GCA CAA AAA GTT GCC ATT CAG CTG TTT CTT GGA CCC AAA TAT GAT GCA 1647 Ala Gin Lys Val Ala He Gin Leu Phe Leu Gly Pro Lys Tyr Asp Ala 510 515 520 CTT GGT AAT TTA TTG GAC TTT TCC GAG AGT TAC AAA GAC TTT TAT GAG 1695 Leu Gly Asn Leu Leu Asp Phe Ser Glu Ser Tyr Lys Asp Phe Tyr Glu 525 530 535 ATT GAC TAC TGG ATT ACT GAT GTG AAT GCT GGC TTG AAT AAA CTT GAA 1743 He Asp Tyr Trp He Thr Asp Val Asn Ala Gly Leu Asn Lys Leu Glu 540 545 550 CGT ACC AGT CAC GAC TTT ATC TTT TTG ATG GCC GAC CGA GAT CCA AGT 1791 Arg Thr Ser His Asp Phe He Phe Leu Met Ala Asp Arg Asp Pro Ser 555 560 565 GAA ATT TTA TAC AAA AGA GTT TTA AAG GCC CTT GAT GGA AGT GAA AAG 1839 Glu He Leu Tyr Lys Arg Val Leu Lys Ala Leu Asp Gly Ser Glu Lys 570 575 580 585 TTC ATG TAC AAA AAG AAT TTG TAT GGC ATT CCG GAA CGT TTA CTT CTA 1887 Phe Met Tyr Lys Lys Asn Leu Tvr Gly He Pro Glu Arg Leu Leu Leu 590 " 595 600 CCA AAA GGT AAA CGT GCC GGT AGT ATT TTC CAA CTG TTT GCC TAT GTA 1935 Pro Lys Gly Lys Arg Ala Gly Ser He Phe Gin Leu Phe Ala Tyr Val 605 610 615 AGC CCA GTT ACC CAG CCA GTC ACC TAC AAA TCA CGA GTA TTT GGA TCT 1983 Ser Pro Val Thr Gin Pro Val Thr Tyr Lys Ser Arg Val Phe Gly Ser 620 625 630 TAT CAA TAC TAC ATG AAA CCA GGT GGT TTT CCA CTG GAC AGG CCA ATC 2031 Tyr Gin Tyr Tyr Met Lys Pro Gly Gly Phe Pro Leu Asp Arg Pro He 635 640 645 TAC TAT CCC CAT TTC CAA GGG CCC AAT ATG TTC TTC AAA GAT ATT ACG 2079 Tyr Tyr Pro His Phe Gin Gly Pro Asn Met Phe Phe Lys Asp He Thr 650 655 660 665 ATT TAC CAC AAG ACT GAT GTG GAT CCT AAT GCT ACT ACC TAATTCCAAT 2128 He Tyr His Lys Thr Asp Val Asp Pro Asn Ala Thr Thr 670 675 TTTTTTACTC TATTTTCATT TGAGATTCTT ATCAAATTCA ATGTTTGTTT GTTAATATTG 2188 TCTTTGTAGA GCTTAGAATG TTAGATTGAA AATGTTTATT TCCATGACAA TTTATTATTT 2248 GTTATTGATA TTATCAATGA ATTCTCTGTC AGTCAACCTC AGAGAATATA AAATTTTATT 2308 ACAAAAATGT CGTATTGAGC ATAAATTCAT TATTTGGGAA AAATTTTCAA ATAAAAAGCA 2368 TATTTTCCAA CAAAAAAAA 2387 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 678 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein 24 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Leu Lys Lys Val Phe Leu Leu Ala Ser Leu Ala He He Val He 1 5 10 15 Lys Ala Asp Thr Asp Phe Tyr Tyr Thr Asp Val He Ala Asp Gin Asp 20 25 30 Phe Leu Leu Lys Gin Lys Lys Val Phe Gin Leu Leu Tyr His Val Ser 35 40 45 Gin Pro Asp He Ser Asn Pro Glu Leu Phe Gin Glu Gly Leu Ala Tyr 50 55 60 Asp He Gly Ala Asn He Asp Ser Tyr Ser Asn Lys Asp Ala Val Asn 65 70 75 80 His Phe Leu Glu Leu Tyr Lys Phe Gly Phe Leu Pro Arg Gly Ala He 85 90 95 Tyr Trp Val Tyr Tyr Pro Lys Leu Leu Asp Glu Thr Lys Ala Leu Phe 100 105 110 Lys Leu Phe Tyr Tyr Ala Lys Asp Phe Asp Thr Phe Tyr Lys Thr Ala 115 120 125 Leu Trp Ala Arg Asn Arg Leu Asn Glu Gly Glu Phe He Cys Ala Phe 130 135 140 Tyr Glu Ala Val He Arg Arg Pro Asp Thr Glu Tyr Leu Gin Leu Pro 145 150 155, 160 Pro Pro Tyr Glu Leu Tyr Pro Tyr Ala Phe Phe Asn Ser Glu Val He 165 170 175 Glu Ala Ala Lys Asn Ala Lys Leu Tyr Asn Lys Leu Val Glu Gly Asn 180 185 190 Ser Tyr He He Tyr Val Asn Tyr Ser Gly Trp Tyr Leu Asn Arg Ala 195 200 205 Tyr Asp Thr Glu Met Arg Val Asn Tyr Phe Leu Glu Asp He Gly Leu 210 . 215 220 Asn Thr Phe Tyr Phe Phe Tyr Arg Met Asp Asn Pro Phe Trp Leu Ser 225 230 235 ' 240 Ser Glu Glu Phe Gly Leu Gin Lys Asn Leu Arg Gly Glu Glu Phe Leu 245 250 255 Tyr Val His Lys Thr Leu Leu Asn Arg Tyr Asn Leu Glu Arg Leu Ala 260 265 270 Asn Gly Leu Glu Lys He Glu Glu Phe Leu Trp Glu Gly Glu Phe Tyr 275 280 285 Pro Gly Tyr Tyr Pro Thr Met Val Tyr Gly Asn Gly Leu Ala Tyr Pro 290 295 300 Gin Arg Pro Gly Met Ser Arg He Pro Pro Tyr Lys Tyr His Tyr Leu 305 310 315 320 Arg Tyr He His Asp He Glu Asp Arg He Ser Thr Ala He Asp Leu 325 330 335 25 Gly Tyr He He Asp Ser Asp Gly Ser His His Asn He Ser Ser Pro 340 345 350 Glu Glv Leu Asn Leu Leu Gly Asn lie lie Glu Gly Asn Glu Asp Ser 355 360 365 Cys Asn Lys Asn Phe Tyr His Ser Leu Asp Trp Tyr Gly Arg Lys Val 370 375 380 Leu Gly Phe Asn Leu Glu Pro Lys Thr Pro Tyr Gin Val He Pro Ser 385 390 395 400 Ala Leu Glu Ser Phe Ser Thr Cys Met Arg Asp Pro Ala Phe Tyr Arg 405 410 415 Leu Tyr Asn Arg Tyr Leu Ser Tyr Trp Tyr Arg Phe Lys Glu Thr Leu 420 425 430 Lys Pro Tyr Ser Lys Asn Glu He Val Phe Ser Asp Leu Lys Phe Glu 435 440 445 Ser He Ala Val Asp Lys Leu He Thr Tyr Phe Asp Tyr Phe Asp Ser 450 455 460 Thr He Ser Asn Gly Leu Pro He Thr Ser Lys Gin Asp Ala Asp Asn 465 470 475 480 Leu Met He Lys Val Arg Gin Ser Arg Leu Asn Asn Lys His Phe Thr 485 490 495 Val His Phe Ala Leu Asn Ser Asp Lys Ala Gin Lys Val Ala He Gin 500 505 510 Leu Phe Leu Gly Pro Lys Tyr Asp Ala Leu Gly Asn Leu Leu Asp Phe 515 520 525 Ser Glu Ser Tyr Lys Asp Phe Tyr Glu He Asp Tyr Trp He Thr Asp 530 535 540 Val Asn Ala Gly Leu Asn Lys Leu Glu Arg Thr Ser His Asp Phe He 545 550 555 560 Phe Leu Met Ala Asp Arg Asp Pro Ser Glu He Leu Tyr Lys Arg Val 565 570 575 Leu Lys Ala Leu Asp Gly Ser Glu Lys Phe Met Tyr Lys Lys Asn Leu 580 585 590 Tyr Gly He Pro Glu Arg Leu Leu Leu Pro Lys Gly Lys Arg Ala Gly 595 600 605 Ser He Phe Gin Leu Phe Ala Tyr Val Ser Pro Val Thr Gin Pro Val 610 615 620 Thr Tyr Lys Ser Arg Val Phe Gly Ser Tyr Gin Tyr Tyr Met Lys Pro 625 630 635 640 Gly Gly Phe Pro Leu Asp Arg Pro He Tyr Tyr Pro His Phe Gin Gly 645 650 655 Pro Asn Met Phe Phe Lys Asp He Thr He Tyr His Lys Thr Asp Val 660 665 670 Asp Pro Asn Ala Thr Thr 675 26 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:6: ARYTGRAANA CYTTYTTYTG 20 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:7: GAYTTYTAYT AYACNGAYGT ' 20 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA 27 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:8: GGAAATCTTG ATCAGCTATC AC 22 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:9: Thr Asp Phe Tyr Tyr Thr Asp Val He Ala Asp Gin Asp Phe Leu Leu 1 5 10 15 Lys Gin Lys Lys Val Phe Gin Leu Leu Tyr His Val Ser Gin Pro 20 25 30 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 93 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: hnear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO 28 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: ACNGAYTTYT AYTAYACNGA YGTNATHGCN GAYCARGAYT TYYTNYTNAA RCARAARAAR 60 GTNTTYCARY TNYTNTAYCA YGTN SNCAR CCN 93 (2) INFORMATION FOR SEQ ID NO:l 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO.ll: GATTTTTATT ATACTGATGT GATAGCTGAT CAAGATTTCC TTTTAAAGCA AAAGAAGGTT 60 TTTCAATT 68 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 12: GACTTTTATT ACACTGACGT GATAGCTGAT CAAGATTTCC TTTTAAAGCA AAAAAAGGTA 60 TTTCAACT 68 29 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single CD) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:13: GATTTTTATT ATACTGATGT GATAGCTGAT CAAGATTTCC TTTTAAAGCA AAAGAAGGTA 60 TTTCAACT 68 30

Claims: WHAT IS CLAIMED IS: 1. A wasp polypeptide substantially free from associated wasp polypeptides which exhibits insect toxicity, and has a molecular weight greater than 70,000. 2. A polypeptide according to claim 1 wherein the wasp is Bracon hebetor. 3. A polypeptide according to claim 2 which is Brh-I (SEQ. ID. NO.: 5) 4. A polypeptide according to claim 2 which is Brh-π. 5. A polypeptide according to claim 2 which is Brh-HI. 6. A polypeptide according to claim 2 which is Brh-IV. 7. A polypeptide according to claim 3 which is Brh-V. 8. A nucleic acid encoding a polypeptide according to either of claims or 3. 9. A nucleic acid according to claim 8, which is a DNA. 10. A vector comprising a nucleic acid of claim 8. 11. A baculovirus whose genome comprises a nucleic acid of claim 8. 12. A method of controlling insects comprising exposing the insects to an insect controlling amount of a polypeptide according to any one of claims 1 to 7. 13. A method of controlling insects comprising infecting the insects with a baculovirus 6 claim 11. 31

Inventors: LEISY DOUGLAS JERALD, QUISTAD GARY BENNET, LEISY, DOUGLAS, JERALD, QUISTAD, GARY, BENNET
Applicants: SANDOZ AG, SANDOZ LTD, SANDOZ LTD., SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., SANDOZ-PATENT-GMBH
Application year: 1993
Main classification: A01N63
IPC codes: A01N37, A01N63, C07K14, C12N7, C12N15, C12P21